Nykode Therapeutics ASA - Notice of Annual General Meeting

20 Apr 2023 07:00 CEST

Oslo, Norway, April 20, 2023 – The Board of Directors of Nykode Therapeutics ASA
(OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of novel immunotherapies, hereby calls for the Annual
General Meeting to be held at meeting room FORUM - Building H, Floor 0 in
Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 11, 2023.

All documents regarding the Annual General Meeting are available at the
Company’s website:
www.nykode.com/investors/corporate-governance/annual-general-meeting/

For further information, please see the Company’s website or contact CFO Harald
Gurvin. Please see below for contact details.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode’s modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen
vaccine, which is exclusively out-licensed to Genentech, a member of the Roche
Group. Additionally, Nykode is conducting a Phase 1/2 trial with next-generation
COVID19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target
collaboration with Regeneron within oncology and infectious diseases and a
collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine
development.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics may be found at
http://www.nykode.com.


Contact for Nykode Therapeutics ASA:
Chief Financial Officer, Harald Gurvin
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway


This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

587994_230420 - NYKD - AGM notice 2023 - ENGLISH.pdf
587994_230420 - NYKD - AGM notice 2023 - NORWEGIAN.pdf